Fenofibrate
Fenofibrate is a fibric acid derivative fibrate compound that exhibits anti-hyperlipidemic, anti-fibrotic, and anticancer chemotherapeutic activities. Fenofibrate activates PPARα, stimulating lipoprotein lipase and increasing lipolysis; this results in decreases in overall triglyceride, VLDL, and LDL levels as well as increases in HDL levels. Fenofibrate decreases oxidative stress-induced expression of α-SMA, TGF-β1, IL-6, collagen-1, and TNF-α, preventing CCL4-induced hepatic fibrosis. Fenofibrate also upregulates expression of Bad, downregulates expression of Bcl-xl, survivin, cyclin D1, and CDK4, activates caspase-3 and NF-κB, and induces G0/G1 phase cell cycle arrest in breast cancer cells, suppressing cell and tumor growth in both in vitro and in vivo models.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18922945
| Cas No. |
49562-28-9 |
|---|---|
| Purity |
≥98% |
| Formula |
C20H21ClO4 |
| Formula Wt. |
360.83 |
| Chemical Name |
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester |
| IUPAC Name |
propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate |
| Synonym |
Ankebin; Elasterin; Fempbrate; Lipantil; Lipoclar; Lipofene; Nolipax; Secalip; Tricor |
| Melting Point |
80-81°C |
| Solubility |
Soluble in acetone, ether, benzene and chloroform. Slightly soluble in methanol and ethanol. Practically insoluble in water. |
| Appearance |
White to off white powder |
Gao Y, Shen W, Zhang Q, et al. Up-regulation of Hepatic VLDLR via PPARα Is Required for the Triglyceride-Lowering Effect of Fenofibrate. J Lipid Res. 2014 Jun 4. [Epub ahead of print]. PMID: 24899625.
Li T, Zhang Q, Zhang J, et al. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway. BMC Cancer. 2014 Feb 16;14:96. PMID: 24529079.
Xie C, Li L, Xu YP, et al. Anti-fibrosis effects of fenofibrate in mice with hepatic fibrosis. Zhonghua Gan Zang Bing Za Zhi. 2013 Dec;21(12):914-9. PMID: 24636293.
